506 related articles for article (PubMed ID: 23125283)
1. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
[TBL] [Abstract][Full Text] [Related]
2. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
3. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression.
Gehrke S; Imai Y; Sokol N; Lu B
Nature; 2010 Jul; 466(7306):637-41. PubMed ID: 20671708
[TBL] [Abstract][Full Text] [Related]
5. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.
Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ
Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-599 regulates the development of Parkinson's disease through mediating LRRK2 expression.
Wu Q; Xi DZ; Wang YH
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):724-731. PubMed ID: 30720180
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients.
Tolosa E; Botta-Orfila T; Morató X; Calatayud C; Ferrer-Lorente R; Martí MJ; Fernández M; Gaig C; Raya Á; Consiglio A; Ezquerra M; Fernández-Santiago R
Neurobiol Aging; 2018 Sep; 69():283-291. PubMed ID: 29935433
[TBL] [Abstract][Full Text] [Related]
8. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity.
Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B
PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193
[TBL] [Abstract][Full Text] [Related]
9. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
10. Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
Dorval V; Mandemakers W; Jolivette F; Coudert L; Mazroui R; De Strooper B; Hébert SS
PLoS One; 2014; 9(1):e85510. PubMed ID: 24427314
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
Lee BD; Dawson VL; Dawson TM
Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
[TBL] [Abstract][Full Text] [Related]
12. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
14. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
17. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 links genetic and sporadic Parkinson's disease.
Kluss JH; Mamais A; Cookson MR
Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
[TBL] [Abstract][Full Text] [Related]
20. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
